Jefferies Group’s Aldeyra Therapeutics ALDX Stock Holding History

Jefferies Group’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$4.31K	Buy	+807	New	+$4.84K	﹤0.01%	1573
2021 Q3	–	Sell	-60,000	Closed	-$680K	–	1690
2021 Q2	$680K	Buy	+60,000	New	+$721K	﹤0.01%	1092
2019 Q4	–	Sell	-14,585	Closed	-$77K	–	2527
2019 Q3	$77K	Buy	+14,585	New	+$78.5K	﹤0.01%	2543
2019 Q2	–	Sell	-20,011	Closed	-$181K	–	2477
2019 Q1	$181K	Buy	+20,011	New	+$170K	﹤0.01%	1967
2018 Q2	–	Sell	-11,900	Closed	-$89K	–	2280
2018 Q1	$89K	Buy	+11,900	New	+$90.3K	﹤0.01%	2081

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Jefferies Group's ALDX Position: Q3 2022 in Review

Jefferies Group opened a new position in Aldeyra Therapeutics (ALDX) in Q3 2022: 807 shares worth $4.31K. The stake represents ﹤0.01% of the portfolio and ranks #1573 among its holdings. This is a return to the name: Jefferies Group previously reported a position in ALDX as recently as Q2 2021.

Jefferies Group first reported a position in ALDX in Q1 2018 and has held it in 5 quarters since. The position peaked at $680K in Q2 2021. 89 funds tracked by Wall St. Rank hold ALDX as of Q3 2022.

Jefferies Group held 807 shares of Aldeyra Therapeutics worth $4.31K as of Q3 2022.
Aldeyra Therapeutics was a new Jefferies Group position in Q3 2022.
Aldeyra Therapeutics made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1573 holding.
Jefferies Group first reported a position in Aldeyra Therapeutics in Q1 2018 and has held it in 5 quarters since.
Jefferies Group's Aldeyra Therapeutics position peaked at $680K in Q2 2021.
89 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.